Findings

What do systematic reviews say?

4 questions · 5 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 1 · 20%Low 1 · 20%Moderate 1 · 20%High 1 · 20%

Dornase alfa vs placebo or no dornase alfa treatment

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

2 findings from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 320 participants
Moderate
Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 647 participants
High

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

FEV1 % predicted · children and young adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dornase alfa vs after airway clearance techniques

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

It is very uncertain whether inhalation of dornase alfa before changes FEV1 (% predicted) change from baseline compared with after airway clearance techniques (very low certainty).

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 0.83
102 participants
Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

FEV1 % predicted · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Low